Nuvisertib (TP-3654): A Comprehensive Profile of a Selective PIM1 Kinase Inhibitor Poised to Address Unmet Needs in Myelofibrosis

I. Executive Summary

Nuvisertib, also known as TP-3654, is an orally available, second-generation small molecule inhibitor of Proviral Integration site for Moloney murine leukemia virus (PIM) kinases, currently under clinical investigation by Sumitomo Pharma America.[1] As a highly selective inhibitor of the PIM1 isoform, Nuvisertib represents a novel therapeutic approach for hematological malignancies, with its most advanced development program focused on myelofibrosis (MF), a rare and debilitating blood cancer.[3] The drug is emerging as a promising agent for patients with intermediate or high-risk MF who are relapsed, refractory, or intolerant to current standard-of-care Janus-associated kinase (JAK) inhibitors.

The strategic value of Nuvisertib is anchored in its distinct mechanism of action, which confers a unique and highly advantageous clinical profile. Unlike existing therapies that are often limited by myelosuppressive toxicities, Nuvisertib has demonstrated a favorable and manageable safety profile, characterized primarily by low-grade, transient gastrointestinal side effects. This benign hematological profile is a direct consequence of its high selectivity for the PIM1 kinase, a pharmacological feature that differentiates it from less selective pan-PIM inhibitors and enables its use in patients with pre-existing cytopenias.

Clinically, Nuvisertib has produced consistent and maturing evidence of durable activity in a heavily pre-treated patient population. Data from the ongoing Phase 1/2 clinical trial (NCT04176198) show meaningful spleen volume reduction, profound and rapid improvement in constitutional symptoms, and, most significantly, objective signs of disease modification. These include improvements in bone marrow fibrosis and sustained enhancements in hemoglobin and platelet counts—endpoints rarely achieved with current therapies, particularly in the relapsed/refractory setting.[3] This clinical activity is strongly correlated with the drug's pharmacodynamic effect of modulating disease-driving inflammatory cytokines.

The therapeutic potential of Nuvisertib has been recognized by global regulatory agencies, as evidenced by a series of positive designations, including Orphan Drug status from the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and Japan's Ministry of Health, Labour and Welfare (MHLW), as well as Fast Track Designation from the FDA.[2] These designations validate the high unmet medical need in myelofibrosis and underscore Nuvisertib's potential to address it.

Collectively, the data position Nuvisertib as a significant potential advancement in the myelofibrosis treatment landscape. Its unique combination of safety and multi-faceted efficacy makes it a strong candidate for monotherapy in later-line settings and an ideal partner for combination with JAK inhibitors to deepen and prolong responses. If the promising results from the current studies are confirmed in pivotal trials, Nuvisertib is poised to become a cornerstone therapy for a substantial segment of patients with myelofibrosis.

II. Molecular and Pharmacological Profile

Chemical Identity and Physicochemical Properties

Nuvisertib is a synthetic organic small molecule compound being developed for its antineoplastic properties.[1] Its identity is well-defined by a comprehensive set of chemical and regulatory identifiers.

• Generic Name: Nuvisertib [7]
• Code Names: TP-3654, SGI-9481 [1]
• DrugBank ID: DB18109 [8]
• CAS Number: 1361951-15-6 [9]
• Type: Small Molecule [8]

The molecular structure of Nuvisertib is precisely defined by its chemical formula and nomenclature, which are crucial for its synthesis, characterization, and interaction with its biological target.

• Chemical Formula: C22​H25​F3​N4​O [9]
• Molecular Weight: 418.46 g/mol (Average); 418.5 Da [8]
• IUPAC Name: 2-((1R,4R)-4-((3-(3-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazin-6-yl)amino)cyclohexyl)propan-2-ol [1]
• Canonical SMILES: CC(C)(C1CCC(CC1)NC2=NN3C(=NC=C3C4=CC(=CC=C4)C(F)(F)F)C=C2)O [9]
• InChIKey: XRNVABDYQLHODA-UHFFFAOYSA-N [9]

For research and formulation purposes, Nuvisertib's solubility has been characterized in various solvents. It is soluble in DMSO up to 50 mg/mL (119.49 mM) or 100 mM and in ethanol to 10 mM.[11] Specific protocols have been developed to prepare stock solutions for

in vitro and in vivo studies, utilizing solvents such as DMSO, PEG300, Tween-80, and corn oil to achieve clear or suspended solutions suitable for administration.[12]

The compound's physicochemical properties, summarized in the table below, are indicative of a molecule designed for oral bioavailability and cell permeability, consistent with its development as an oral therapeutic.

Property	Value	Source
logP	4.59	8
pKa (Strongest Acidic)	19.29	8
pKa (Strongest Basic)	3.32	8
Polar Surface Area	62.45 A˚2	8
Hydrogen Bond Donors	2	8
Hydrogen Bond Acceptors	4	8
Rotatable Bond Count	5	8

Mechanism of Action: Selective PIM Kinase Inhibition

The therapeutic rationale for Nuvisertib is rooted in its targeted inhibition of the PIM kinase family, which plays a critical role in cancer cell survival and proliferation.

The PIM Kinase Family as an Oncogenic Target

The PIM kinase family comprises three isoforms—PIM1, PIM2, and PIM3—which are proto-oncogenic serine/threonine kinases.[1] Unlike many other kinases, PIM kinases are constitutively active and their functional regulation occurs primarily at the level of transcription and protein stability.[1] They are key downstream effectors in multiple signaling pathways crucial for cell growth and immune responses, most notably the JAK/STAT pathway.[11] In myelofibrosis, the JAK/STAT pathway is frequently dysregulated due to driver mutations (e.g.,

JAK2 V617F), leading to upregulation of target genes, including PIM1.[14] The overexpression of PIM1 in MF hematopoietic cells promotes uncontrolled cell proliferation and survival by phosphorylating downstream substrates that suppress apoptosis, making it a highly attractive therapeutic target.[1]

Binding Kinetics and Target Selectivity Profile

Nuvisertib functions as an orally available, selective, and ATP-competitive inhibitor of PIM kinases.[1] It binds to the ATP-binding pocket of the kinases, preventing them from phosphorylating their downstream substrates. The defining characteristic of Nuvisertib is its potent and highly selective inhibition of the PIM1 isoform relative to the other family members. Its inhibitory constants (

Ki​) have been determined as:

• PIM1: 5 nM [10]
• PIM3: 42 nM [10]
• PIM2: 239 nM [10]

This profile demonstrates an approximately 8-fold greater selectivity for PIM1 over PIM3 and a nearly 48-fold selectivity for PIM1 over PIM2. While highly selective for PIM1, it is not entirely specific; broader kinase screening revealed that Nuvisertib can inhibit 19 other kinases, including PI3K isoforms (PI3Kα, PI3Kγ, and PI3Kδ), with IC50​ values below 300 nM.[17]

This high degree of selectivity for PIM1 is not merely a pharmacological detail but appears to be a central driver of Nuvisertib's favorable clinical safety profile. Preclinical studies have established a critical distinction between the roles of PIM isoforms in hematopoiesis. Genetic knockout experiments in mice revealed that pan-PIM knockout, which ablates all three isoforms, results in decreased platelet counts.[18] In contrast, a selective PIM1 knockout was shown to prevent the progression of myelofibrosis without adversely affecting platelet counts.[18] This preclinical observation correlates directly with the clinical data from the NCT04176198 trial, which consistently reports a lack of significant myelosuppressive adverse events and stable hemoglobin and platelet counts throughout treatment.[5] This strongly suggests that by selectively targeting PIM1 and largely sparing PIM2 and PIM3, Nuvisertib effectively targets the disease-driving kinase while avoiding the on-target toxicity (thrombocytopenia) associated with broader PIM inhibition. This characteristic represents a major strategic advantage, enabling its use in patients with baseline cytopenias who are often poor candidates for other myelosuppressive therapies.

Downstream Signaling Consequences

By inhibiting PIM kinase activity, Nuvisertib blocks the activation of PIM-mediated signaling pathways, thereby inhibiting the proliferation of cells that overexpress PIM.[1] Mechanistic studies in

JAK2 V617F mutant hematopoietic cells have shown that treatment with TP-3654 leads to significant inhibition of critical downstream oncogenic signaling nodes, including the mTORC1, MYC, and TGF-β pathways.[15] This provides a direct molecular link between PIM1 inhibition and the attenuation of key pathological processes in myelofibrosis, such as aberrant cell growth and fibrosis.

The engagement of this mechanism has been confirmed through pharmacodynamic assessments in cellular assays. In an overexpression system using HEK293 cells, TP-3654 demonstrated potent, PIM1-specific cellular activity, inhibiting the phosphorylation of BAD (a known PIM substrate) with an average half maximal effective concentration (EC50​) of 67 nM.[12] This effect was also observed in the UM-UC-3 bladder cancer cell line, providing further evidence of on-target activity in a cancer context.[20]

III. Preclinical Evidence and Rationale for Clinical Development

An extensive body of preclinical research has validated the therapeutic potential of Nuvisertib, establishing a strong scientific rationale for its clinical investigation in both solid tumors and hematological malignancies.

In Vitro Antineoplastic Activity

At the cellular level, Nuvisertib has demonstrated potent and targeted activity against cancer cells driven by PIM kinase signaling.

• Hematological Malignancy Cell Lines: Nuvisertib shows a marked ability to inhibit the proliferation of hematopoietic cell lines harboring the driver mutations central to myeloproliferative neoplasms. It significantly reduces the growth of murine Ba/F3 cells and human cell lines (HEL, SET-2, UKE-1) that express the clinically relevant JAK2 V617F and MPL W515L mutations.[15] Furthermore, treatment with Nuvisertib induces significant apoptosis in these mutant-expressing cell lines, while having only modest effects on wild-type cells.[15] This demonstrates a preferential cytotoxic effect on the malignant cell population, a highly desirable characteristic for a targeted therapy.
• Solid Tumor Cell Lines: The compound's activity extends to solid tumors. Studies have shown that Nuvisertib reduces colony growth in human bladder cancer cell lines (T24, UM-UC-3) and prostate cancer cells (PC-3).[12] This broad anti-proliferative activity provided the initial justification for exploring Nuvisertib in patients with advanced solid tumors.
• Pharmacodynamic Confirmation: Target engagement was confirmed in the UM-UC-3 bladder cancer cell line, where treatment with Nuvisertib led to a measurable reduction in the phosphorylation of the PIM substrate BAD.[12] This finding verified that the observed anti-proliferative effects were indeed mediated through the intended PIM kinase inhibition pathway.

In Vivo Efficacy in Murine Models

The promising in vitro results were successfully translated into significant therapeutic effects in animal models, providing the direct impetus for advancing Nuvisertib into human clinical trials for myelofibrosis.

• Myelofibrosis Models: In genetically engineered mouse models that recapitulate human myelofibrosis (driven by JAK2 V617F or MPL W515L mutations), oral administration of Nuvisertib as a monotherapy produced significant improvements in key disease hallmarks. Treatment led to marked reductions in elevated white blood cell counts (leukocytosis), spleen size (splenomegaly), and, most importantly, attenuated the degree of bone marrow fibrosis.[14]
• Combination with Ruxolitinib: When Nuvisertib was combined with the approved JAK inhibitor ruxolitinib in these same MF models, the therapeutic effects were substantially enhanced. The combination therapy resulted in a synergistic or additive effect that almost completely normalized white blood cell and neutrophil counts, dramatically reduced spleen size, and nearly eliminated bone marrow fibrosis.[22] These powerful preclinical data established the strong rationale for investigating Nuvisertib both as a single agent and as a combination partner for JAK inhibitors.
• Solid Tumor Xenograft Models: In mouse xenograft models using human solid tumor cell lines, Nuvisertib also demonstrated robust anti-tumor activity. Oral dosing at 200 mg/kg significantly inhibited the growth of established UM-UC-3 (bladder) and PC-3 (prostate) tumors. This efficacy was achieved without any signs of gross toxicity or significant changes in animal body weight, indicating a favorable therapeutic index.[12] These results provided the final piece of preclinical evidence needed to initiate the first-in-human clinical trial.

Ancillary Pharmacological Activity: Reversal of ABCG2-Mediated Multidrug Resistance

In addition to its primary mechanism as a PIM kinase inhibitor, further research has uncovered a distinct and potentially valuable pharmacological property of Nuvisertib: the ability to counteract a specific form of multidrug resistance (MDR) in cancer cells.[26]

• Mechanism of MDR Reversal: Studies revealed that Nuvisertib is a potent and selective modulator of the ATP-binding cassette subfamily G member 2 (ABCG2) drug efflux pump, also known as breast cancer resistance protein (BCRP).[26] ABCG2 is a transmembrane transporter that actively pumps a wide range of cytotoxic chemotherapy drugs out of cancer cells, thereby reducing their intracellular concentration and rendering the cells resistant to treatment. Nuvisertib itself is not a substrate for ABCG2 and its cytotoxicity is unaffected by the pump's expression. However, it effectively interferes with the transport function of ABCG2. By attenuating the pump's activity, Nuvisertib can resensitize ABCG2-overexpressing cancer cells to conventional cytotoxic agents that are ABCG2 substrates, such as topotecan, SN-38 (the active metabolite of irinotecan), and mitoxantrone.[13]

This secondary activity presents a latent therapeutic profile for Nuvisertib as a chemosensitizing agent, creating potential long-term strategic options beyond its current development path. Multidrug resistance remains a primary cause of treatment failure across numerous cancer types, and the upregulation of efflux pumps like ABCG2 is a common mechanism. The discovery that Nuvisertib can effectively reverse this resistance pathway in vitro suggests a plausible future application. While the immediate clinical focus for Nuvisertib is squarely on its PIM1-inhibitory effects in myelofibrosis, this ancillary property could be leveraged for future life-cycle management. It opens the possibility for development as a combination therapy partner aimed at restoring or enhancing the efficacy of standard chemotherapies in patients with solid tumors or hematological malignancies known to develop ABCG2-mediated resistance. This adds a layer of strategic depth to the asset, with potential for expansion into new indications and therapeutic settings.

IV. Clinical Development Program

The clinical development of Nuvisertib has progressed logically from an initial safety-establishing study in solid tumors to a comprehensive, multi-arm pivotal study in its primary indication of myelofibrosis.

Early Phase Solid Tumor Study (NCT03715504)

The first-in-human evaluation of Nuvisertib was a Phase 1, open-label, dose-escalation study in patients with advanced, unresectable, or metastatic solid tumors who were refractory to standard therapies.[27]

• Objectives: The primary goal was to determine the maximum tolerated dose (MTD), identify any dose-limiting toxicities (DLTs), and establish the initial safety and pharmacokinetic (PK) profile of orally administered Nuvisertib.[27]
• Key Findings: The study successfully demonstrated that Nuvisertib was well-tolerated as a monotherapy in a heavily pretreated patient population. No DLTs were observed, and there were no Grade 4 or 5 adverse events.[28] While not a primary endpoint, the study showed preliminary signals of antitumor activity, with 6 of 10 patients achieving stable disease for a median duration of 5.5 months. Notably, one patient with colorectal cancer who had failed four prior lines of therapy experienced a 22% reduction in tumor volume and maintained stable disease for over five months.[28] Pharmacokinetic analysis confirmed that plasma concentrations ( Cmax​) and overall exposure (AUC) of Nuvisertib increased with escalating doses.[28] This foundational study provided the critical human safety and exposure data required to confidently advance Nuvisertib into studies for hematological malignancies.

Pivotal Myelofibrosis Study (NCT04176198)

The cornerstone of Nuvisertib's clinical program is the ongoing, global Phase 1/2 study in myelofibrosis, which has systematically evaluated its safety and efficacy and has strategically expanded over time to explore its full therapeutic potential.

Trial Design and Methodology

• Title: A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis.[29]
• Patient Population: The trial was designed to address a significant unmet need by enrolling patients with primary or post-polycythemia vera/post-essential thrombocythemia MF who were relapsed, refractory, intolerant to, or otherwise ineligible for treatment with approved JAK inhibitors.[14] A key inclusion criterion is a platelet count of ≥25×109/L, a notably low threshold that allows for the enrollment of patients with thrombocytopenia who are often excluded from other trials.[5]
• Dose Escalation and Regimen: The study explored a range of oral doses, starting from 480 mg once daily (QD) and escalating to 720 mg twice daily (BID), with some cohorts exploring doses as high as 1440 mg BID.[5] Later analyses have focused on the efficacy observed at the 720 mg BID dose level.[6]
• Endpoints: The primary endpoints of the dose-escalation phase are to assess safety and tolerability and to determine the MTD and/or the recommended Phase 2 dose (RP2D). Secondary and exploratory endpoints are comprehensive, including spleen volume reduction (SVR), improvement in total symptom score (TSS), changes in bone marrow fibrosis (BMF), overall survival, and detailed pharmacokinetic and pharmacodynamic (e.g., cytokine modulation) assessments.[5]

The trial's design has evolved from a single-arm monotherapy study into a multi-arm platform trial, reflecting a strategic expansion based on promising early data and a strong preclinical rationale for combination therapy.

Arm	Description	Patient Population	Rationale
Arm 1	Nuvisertib Monotherapy	Patients with R/R MF, or those ineligible for JAK inhibitors.	Establish single-agent safety and efficacy in a population with high unmet need.
Arm 2	Nuvisertib Add-on to Ruxolitinib	Patients on a stable dose of ruxolitinib for ≥6 months with a suboptimal or lost response.	Evaluate the ability of Nuvisertib to deepen or recapture response to JAK inhibition in a second-line setting.
Arm 3	Nuvisertib Combination with Momelotinib	Patients previously treated with a JAK inhibitor (other than momelotinib).	Explore a novel combination targeting patients with MF and anemia, leveraging momelotinib's specific benefits.

Table populated with data from.[18]

Clinical Safety and Tolerability Profile

Across multiple data presentations spanning several years, a consistent and favorable safety profile has been a hallmark of Nuvisertib treatment.

• Overall Tolerability: The drug has been consistently reported as well-tolerated.[3] No DLTs have occurred in the dose-escalation phase, and an MTD has not been reached, indicating a wide therapeutic window.[3]
• Adverse Events: The most common treatment-related adverse events (TRAEs) are predominantly Grade 1 or 2 gastrointestinal issues, including diarrhea, nausea, and vomiting. These events are typically transient, resolving within the first few weeks of treatment, and are manageable with standard supportive care.[24]
• Hematological Safety: The lack of significant myelosuppression is a key differentiating feature. Unlike JAK inhibitors, which are frequently associated with anemia and thrombocytopenia, Nuvisertib treatment has been associated with stable mean hemoglobin and platelet counts over 24 weeks of therapy.[5] This superior hematological safety profile is critical for the target patient population and supports its potential for combination with other agents without compounding cytopenic toxicities.[18]

Clinical Efficacy in Relapsed/Refractory Myelofibrosis

Nuvisertib has demonstrated compelling and durable clinical activity in the difficult-to-treat R/R MF population. The longitudinal data presented at major hematology conferences show a maturing and consistent efficacy profile.

Data Cutoff / Conference	N (Evaluable)	SVR ≥25% (SVR25)	TSS ≥50% (TSS50)	BMF Improvement (≥1 Grade)	Hemoglobin Response	Platelet Response
ASH 2022 34	8	2/8 (25%) achieved ≥35% SVR	5/8 (62.5%)	Not Reported	Not Reported	Not Reported
EHA 2023 19	10	2/10 (20%) achieved ≥35% SVR	6/10 (60%)	1 patient	Not Reported	Not Reported
ASH 2024 5	16	5/16 (31%)	8/16 (50%)	6/18 (33%)	6/18 (33%)	7/22 (32%)
EHA 2025 3	18	4/18 (22.2%)	8/18 (44.4%)	12/28 (42.9%)	6/25 (24%)	8/30 (26.7%)

Note: The number of evaluable patients (N) varies between endpoints and across presentations due to different data cutoff dates and patient follow-up times.

• Spleen and Symptom Responses: Nuvisertib induces both spleen volume reduction and profound symptom improvement. Responses are observed as early as four weeks into therapy and have proven to be durable, with a substantial number of patients remaining on active treatment for more than a year.[6] The most recent data from the EHA 2025 Congress reported a SVR25 rate of 22.2% and a TSS50 rate of 44.4% in evaluable patients.[3]
• Evidence of Disease Modification: Perhaps the most significant finding is Nuvisertib's potential to alter the natural history of the disease, an effect not typically seen with JAK inhibitor monotherapy.
• Bone Marrow Fibrosis Improvement: A remarkable 42.9% of evaluable patients have shown an improvement of at least one grade in bone marrow fibrosis, a core pathological feature of MF.[3] This reversal of fibrosis is a strong indicator of disease-modifying activity.
• Hematological Improvement: In a patient population often defined by worsening cytopenias, Nuvisertib has demonstrated the ability to improve blood counts. As of EHA 2025, 24% of evaluable patients achieved a hemoglobin response (e.g., ≥1.0 g/dL increase sustained for ≥12 weeks without transfusion), and 26.7% achieved a platelet response (e.g., ≥30×109/L increase maintained for ≥4 weeks).[3]

Pharmacokinetic and Pharmacodynamic Insights

• Pharmacokinetics (PK): The clinical program is designed to fully characterize the absorption, distribution, metabolism, and excretion (ADME) profile of Nuvisertib.[29] A dedicated Phase 1 study is currently underway to specifically assess the effect of food on the drug's absorption and to compare the relative bioavailability of its capsule and tablet formulations, which will inform final dosing recommendations.[38]
• Pharmacodynamics (PD) and Cytokine Modulation: A highly robust and consistent pharmacodynamic finding is the profound effect of Nuvisertib on the inflammatory cytokine milieu that drives MF. Treatment leads to rapid (observed as early as 24 hours) and broad reductions in pro-inflammatory cytokines such as IL-6, IL-8, EN-RAGE, and MIP-1$\beta$, while increasing levels of anti-inflammatory cytokines like adiponectin.[3]

This strong pharmacodynamic effect provides a clear mechanistic link between PIM1 inhibition and clinical benefit. Myelofibrosis is understood to be a disease driven by a storm of inflammatory cytokines, which are responsible for both the debilitating constitutional symptoms and the progressive bone marrow fibrosis.[19] The rapid and broad modulation of these cytokines by Nuvisertib directly addresses this underlying pathology. Crucially, a statistically significant correlation (

p<0.001) has been established between the magnitude of cytokine reduction and the degree of clinical response, particularly in symptom improvement (TSS).[3] This finding suggests that a patient's cytokine profile could potentially serve as an early predictive biomarker of response. An individual exhibiting a rapid and deep reduction in key inflammatory markers after initiating therapy may be more likely to achieve a durable and meaningful clinical benefit. This opens the door for future personalized medicine strategies, where early pharmacodynamic markers could be used to guide dosing or patient selection.

V. Regulatory and Strategic Landscape

Nuvisertib's progression through clinical development has been bolstered by significant positive engagement from major global regulatory agencies, reflecting a consensus on its potential to address a serious unmet medical need.

Regulatory Milestones and Their Significance

Sumitomo Pharma has successfully secured several key regulatory designations for Nuvisertib, which not only provide development incentives but also serve as important external validation of the drug's therapeutic promise.

• U.S. Food and Drug Administration (FDA):
• Orphan Drug Designation (May 2022): This designation is granted to drugs intended for rare diseases (affecting fewer than 200,000 people in the U.S.). It provides benefits such as tax credits for clinical trials, waiver of prescription drug user fees, and potential for seven years of market exclusivity upon approval.[39]
• Fast Track Designation (June 2025): This is a critical milestone that accelerates the development and review of drugs for serious conditions that fill an unmet medical need. It allows for more frequent meetings with the FDA, eligibility for Accelerated Approval and Priority Review, and a rolling review of the marketing application.[3] This designation significantly de-risks the development timeline and signals the FDA's recognition of Nuvisertib's potential.
• Global Designations:
• Japan Ministry of Health, Labour and Welfare (MHLW) Orphan Drug Designation (November 2024): This provides similar development and market exclusivity benefits in Japan, a key pharmaceutical market.[3]
• European Medicines Agency (EMA) Orphan Drug Designation (July 2025): Granted for conditions affecting no more than 5 in 10,000 people in the EU, this designation provides access to centralized authorization procedures, protocol assistance, and up to ten years of market exclusivity in Europe.[2]

The sequential acquisition of these designations from the world's three primary regulatory bodies creates a powerful narrative. It demonstrates a global consensus among health authorities that myelofibrosis remains an area of high unmet need and that Nuvisertib represents a credible and promising approach to addressing this need.

Competitive Positioning in the Myelofibrosis Treatment Paradigm

Nuvisertib is entering a dynamic but challenging therapeutic landscape. Its unique profile positions it to carve out a significant role, both as a monotherapy and as a combination agent.

• Versus Approved JAK Inhibitors: The primary approved therapies for MF are JAK inhibitors like ruxolitinib, fedratinib, pacritinib, and momelotinib. While effective at reducing spleen size and symptoms for many, their utility is often limited by dose-dependent cytopenias (anemia and thrombocytopenia), and they rarely induce deep responses like the reversal of bone marrow fibrosis.[14] Nuvisertib's key competitive advantages are its differentiated safety profile, particularly the lack of significant myelosuppression, and its demonstrated ability to improve BMF and hematological parameters. This positions it as an ideal therapy for patients who are intolerant to JAK inhibitors, have become resistant, or have baseline cytopenias that preclude the use of JAK inhibitors at effective doses.[18]
• As a Combination Partner: The strong preclinical data showing synergy with ruxolitinib, coupled with the lack of overlapping hematological toxicities, makes Nuvisertib an exceptionally attractive combination partner.[15] The expansion of the NCT04176198 trial to include combination arms with both ruxolitinib and momelotinib is a direct execution of this strategy.[18] The goal is to show that adding Nuvisertib to a JAK inhibitor backbone can deepen initial responses, recapture responses in patients who are failing, and prolong the duration of benefit, potentially moving PIM1 inhibition into earlier lines of therapy.
• Versus Other Investigational Agents: The MF pipeline is active, with other novel mechanisms being explored, such as BET inhibition (pelabresib) and BCL-xL inhibition (navitoclax). While these agents have also shown promise in combination with ruxolitinib, some have demonstrated overlapping toxicities. For instance, navitoclax is associated with thrombocytopenia, which could complicate its combination with JAK inhibitors.[18] Nuvisertib's benign hematological profile may therefore remain a key competitive differentiator as these various combination strategies mature.

Developer and Future Outlook

Nuvisertib is being developed by Sumitomo Pharma America, Inc., and its global oncology division, Sumitomo Pharma Oncology, Inc., which are subsidiaries of the Japan-based Sumitomo Pharma Co., Ltd..[4] Nuvisertib is prominently featured as a key mid-stage asset in the company's oncology pipeline, indicating a strong corporate commitment to its development.[41]

The clinical development path for Nuvisertib appears clear and strategically sound:

1. Finalize Monotherapy RP2D: Complete the dose expansion in Arm 1 of NCT04176198 to confirm the optimal dose and schedule for future pivotal studies.
2. Generate Combination Data: Obtain robust safety and efficacy data from the combination arms with ruxolitinib (Arm 2) and momelotinib (Arm 3) to validate its role as a combination agent.
3. Initiate Pivotal Trial: Based on the strength of the Phase 1/2 data, launch a registrational Phase 3 trial, most likely evaluating Nuvisertib monotherapy in the relapsed/refractory MF setting where the unmet need is highest.
4. Expand to Frontline: If the add-on and combination data are compelling, a subsequent Phase 3 trial evaluating a Nuvisertib-JAK inhibitor combination in treatment-naïve patients would be a logical next step.
5. Long-Term Opportunities: Further in the future, the company could explore Nuvisertib's potential in other PIM-driven hematological malignancies or leverage its unique ABCG2-modulating properties to develop it as a chemosensitizer in solid tumors.

VI. Synthesis and Expert Conclusion

SWOT Analysis

A strategic assessment of Nuvisertib reveals a profile with significant strengths and clear opportunities, balanced by the inherent risks of mid-stage clinical development.

• Strengths:
• Differentiated Mechanism: Highly selective PIM1 inhibition targets a key downstream node of the dysregulated JAK/STAT pathway.
• Compelling Safety Profile: Lack of significant myelosuppression is a major advantage over current standards of care and some pipeline competitors.
• Evidence of Disease Modification: Demonstrated improvements in bone marrow fibrosis and hematological parameters suggest an ability to alter the disease course.
• Robust Efficacy Data: Consistent and durable spleen, symptom, and hematological responses in a difficult-to-treat relapsed/refractory population.
• Strong Regulatory Validation: Multiple Orphan Drug and Fast Track designations from global health authorities de-risk the development path.
• Weaknesses:
• Mid-Stage Data: Efficacy and safety data are from a Phase 1/2 open-label study; confirmation in a large, randomized, controlled Phase 3 trial is still required.
• Long-Term Profile: The full long-term safety and durability profile is still being established as patient follow-up continues.
• Opportunities:
• High Unmet Need: A clear and commercially viable path to market exists in the relapsed/refractory MF population with limited options.
• Combination Therapy Cornerstone: Potential to become the preferred combination partner for JAK inhibitors across multiple lines of therapy due to its non-overlapping toxicity profile.
• Pipeline Expansion: The ancillary MDR-reversal mechanism provides a scientifically sound basis for future exploration in other oncology indications.
• Threats:
• Competitive Landscape: The myelofibrosis pipeline is active, and other novel agents or combinations could demonstrate superior efficacy or safety in pivotal trials.
• Development Risk: The possibility of unforeseen long-term toxicities or failure to meet primary endpoints in a Phase 3 study remains an inherent risk for any investigational agent.

Expert Opinion and Final Assessment

Nuvisertib (TP-3654) has emerged as one of the most promising and rationally designed therapeutic agents in the mid-stage clinical pipeline for myelofibrosis. Its development program has been characterized by a methodical translation of a strong preclinical rationale into compelling and consistent clinical data.

The molecule's defining feature is its unique combination of a benign hematological safety profile and evidence of multi-faceted, disease-modifying clinical benefit. By selectively targeting PIM1, Nuvisertib appears to have successfully uncoupled the desired therapeutic effect from the dose-limiting cytopenias that plague many other agents in this space. This allows it to address the critical unmet needs of patients who cannot tolerate or have failed existing JAK inhibitors. The demonstration of improvements not only in symptoms and spleen size but also in the underlying pathology of bone marrow fibrosis and in hematological parameters elevates Nuvisertib from a purely palliative therapy to one with the potential to alter the natural history of the disease.

The strategic execution of its clinical development, including the early expansion into combination therapy arms, and the strong validation from major global regulatory bodies, provides a clear and accelerated path forward. While the ultimate confirmation of its value awaits the results of a pivotal Phase 3 trial, the current trajectory of positive data is exceptionally strong. If this momentum is maintained, Nuvisertib is well-positioned to become a new standard of care for a significant and underserved segment of the myelofibrosis patient population and a valuable new tool in the armamentarium against this challenging disease.

Works cited

1. Definition of PIM kinase inhibitor TP-3654 - NCI Drug Dictionary, accessed September 13, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/nuvisertib
2. Sumitomo Pharma America Announces that the European Medicines Agency Has Granted Orphan Drug Designation to Nuvisertib (TP-3654) for the Treatment of Myelofibrosis - PR Newswire, accessed September 13, 2025, https://www.prnewswire.com/news-releases/sumitomo-pharma-america-announces-that-the-european-medicines-agency-has-granted-orphan-drug-designation-to-nuvisertib-tp-3654-for-the-treatment-of-myelofibrosis-302517571.html
3. Sumitomo Pharma America Announces that Nuvisertib (TP-3654) Has Received FDA Fast Track Designation for the Treatment of Myelofibrosis - Jun 12, 2025, accessed September 13, 2025, https://news.us.sumitomo-pharma.com/2025-06-12-Sumitomo-Pharma-America-Announces-that-Nuvisertib-TP-3654-Has-Received-FDA-Fast-Track-Designation-for-the-Treatment-of-Myelofibrosis
4. Sumitomo Pharma America Announces that Nuvisertib (TP-3654) Has Received FDA Fast Track Designation for the Treatment of Myelofibrosis - PR Newswire, accessed September 13, 2025, https://www.prnewswire.com/news-releases/sumitomo-pharma-america-announces-that-nuvisertib-tp-3654-has-received-fda-fast-track-designation-for-the-treatment-of-myelofibrosis-302480390.html
5. Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, Showed Durable Clinical Response and Sustained Hematological Improvement in Relapsed/Refractory Myelofibrosis Patients - Scholarship@Miami, accessed September 13, 2025, https://scholarship.miami.edu/esploro/outputs/journalArticle/Nuvisertib-TP-3654-an-Investigational-Selective-PIM1/991032490755702976
6. Efficacy and safety of nuvisertib in MF: Preliminary phase I/II data, accessed September 13, 2025, https://mpn-hub.com/medical-information/efficacy-and-safety-of-nuvisertib-in-mf-preliminary-phase-iii-data
7. nuvisertib | Ligand page - IUPHAR/BPS Guide to PHARMACOLOGY, accessed September 13, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13215
8. TP-3654: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed September 13, 2025, https://go.drugbank.com/drugs/DB18109
9. 2-((1r,4r)-4-((3-(3-(Trifluoromethyl)phenyl)imidazo[1,2-b]pyridazin-6-yl)amino)cyclohexyl)propan-2-ol | C22H25F3N4O | CID 66598080 - PubChem, accessed September 13, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/tp-3654
10. TP-3654 | 99.94%(HPLC) | In Stock | Pim inhibitor - Selleck Chemicals, accessed September 13, 2025, https://www.selleckchem.com/products/tp-3654.html
11. TP-3654 (CAS 1361951-15-6) - Abcam, accessed September 13, 2025, https://www.abcam.com/en-us/products/biochemicals/tp-3654-ab286959
12. TP-3654 | Pim Kinase Inhibitor - MedchemExpress.com, accessed September 13, 2025, https://www.medchemexpress.com/TP-3654.html
13. Structure and analysis of TP-3654. (A) TP-3654 compound structure is... - ResearchGate, accessed September 13, 2025, https://www.researchgate.net/figure/Structure-and-analysis-of-TP-3654-A-TP-3654-compound-structure-is-shown-B_fig1_263321239
14. A PHASE 1 STUDY OF TP-3654, AN ORAL PIM KINASE INHIBITOR, IN... - Lebedinsky C, accessed September 13, 2025, https://library.ehaweb.org/eha/2021/eha2021-virtual-congress/324385/claudia.lebedinsky.a.phase.1.study.of.tp-3654.an.oral.pim.kinase.inhibitor.in.html?f=listing%3D3%2Abrowseby%3D8%2Asortby%3D1%2Amedia%3D1
15. Genetic ablation of Pim1 or pharmacologic inhibition with TP-3654 ameliorates myelofibrosis in murine models - PMC, accessed September 13, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8891046/
16. TP-3654 - RayBiotech, accessed September 13, 2025, https://www.raybiotech.com/tp-3654-332-11965
17. TP-3654 (CAS Number: 1361951-15-6) | Cayman Chemical, accessed September 13, 2025, https://www.caymanchem.com/product/29571/tp-3654
18. A Phase 1/2 Study of Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, in Combination with JAK Inhibitors Ruxolitinib or Momelotinib in Patients with Myelofibrosis | Blood | American Society of Hematology, accessed September 13, 2025, https://ashpublications.org/blood/article/144/Supplement%201/6629/527865/A-Phase-1-2-Study-of-Nuvisertib-TP-3654-an
19. P1031: PRELIMINARY DATA FROM THE PHASE 1/2 STUDY OF TP-3654, AN INVESTIGATIONAL SELECTIVE PIM1 KINASE INHIBITOR, SHOWED CYTOKINE REDUCTION AND CLINICAL RESPONSES IN RELAPSED/REFRACTORY MYELOFIBROSIS, accessed September 13, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10431443/
20. TP-3654 | CAS#1361951-15-6 | Pim-1 & Pim-3 Kinase Inhibitor - MedKoo Biosciences, accessed September 13, 2025, https://www.medkoo.com/products/12484
21. Product Data Sheet - MedchemExpress.com, accessed September 13, 2025, https://file.medchemexpress.com/batch_PDF/HY-101126/TP-3654-DataSheet-MedChemExpress.pdf
22. The PIM Kinase Inhibitor TP-3654 in Combination with Ruxolitinib Exhibits Marked Improvement of Myelofibrosis in Murine Models | Blood | American Society of Hematology, accessed September 13, 2025, https://ashpublications.org/blood/article/132/Supplement%201/54/265606/The-PIM-Kinase-Inhibitor-TP-3654-in-Combination
23. news.us.sumitomo-pharma.com, accessed September 13, 2025, https://news.us.sumitomo-pharma.com/2025-06-12-Sumitomo-Pharma-America-Announces-that-Nuvisertib-TP-3654-Has-Received-FDA-Fast-Track-Designation-for-the-Treatment-of-Myelofibrosis#:~:text=About%20Nuvisertib%20(TP%2D3654)&text=Nuvisertib%20was%20observed%20to%20inhibit,clinically%20relevant%20JAK2%20V617F%20mutation.
24. TP-3654 Demonstrates Favorable Tolerability, Early Clinical Activity ..., accessed September 13, 2025, https://www.onclive.com/view/tp-3654-demonstrates-favorable-tolerability-early-clinical-activity-in-r-r-myelofibrosis
25. Sumitomo Pharma Oncology to Present Preliminary Clinical Data Evaluating Investigational Agent TP-3654 at the 64th ASH Annual Meeting & Exposition - Massachusetts Biotechnology Council, accessed September 13, 2025, https://www.massbio.org/news/member-news/sumitomo-pharma-oncology-to-present-preliminary-clinical-data-evaluating-investigational-agent-tp-3654-at-the-64th-ash-annual-meeting-exposition/
26. The Second-Generation PIM Kinase Inhibitor TP-3654 Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs - PMC, accessed September 13, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8431370/
27. Study of TP-3654 in Patients With Advanced Solid Tumors - ClinicalTrials.gov, accessed September 13, 2025, https://clinicaltrials.gov/study/NCT03715504?term=AREA%5BBasicSearch%5D(myovant%20OR%20Sunovion%20OR%20Sumitomo%20Pharma%20Oncology%20OR%20Urovant%20OR%20Enzyvant)&rank=2
28. A phase I, first-in-human, open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP-3654 administered daily for 28 days to patients with advanced solid tumors. | Journal of Clinical Oncology - ASCO Publications, accessed September 13, 2025, https://ascopubs.org/doi/10.1200/JCO.2020.38.15_suppl.3586
29. A Phase 1/2, Open-label, Dose escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP 3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis | Joint Clinical Trials Office, accessed September 13, 2025, https://jcto.weill.cornell.edu/open_clinical_trials/a-phase-12-open-label-dose-escalation-safety-pharmacokinetic-and-pharmacodynamic-study-of-oral-tp-3654-in-patients-with-intermediate-or-high-risk-primary-or-secondary-myelofibrosis
30. A Study of Oral TP-3654 in Patients With Myelofibrosis | Fred Hutchinson Cancer Center, accessed September 13, 2025, https://www.fredhutch.org/en/research/clinical-trials/trial-details.fh_trial_id_14987.a-study-of-oral-tp-3654-in-patients-with-myelofibrosis.html
31. ASH: Preliminary Clinical Data for TP-3654 in Myelofibrosis - OncLive, accessed September 13, 2025, https://www.onclive.com/view/ash-preliminary-clinical-data-for-tp-3654-in-myelofibrosis
32. NCT04176198 | A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis, accessed September 13, 2025, https://clinicaltrials.gov/study/NCT04176198
33. Investigating the efficacy of TP-3654 in patients with myelofibrosis: results from Phase I study, accessed September 13, 2025, https://www.youtube.com/watch?v=RAgcZ6vY_VE
34. Sumitomo Pharma Oncology Presents Preliminary Data from Phase 1/2 Clinical Study Evaluating Investigational Agent TP-3654 in Patients with Myelofibrosis at American Society of Hematology 2022 Annual - Massachusetts Biotechnology Council, accessed September 13, 2025, https://www.massbio.org/news/member-news/sumitomo-pharma-oncology-presents-preliminary-data-from-phase-1-2-clinical-study-evaluating-investigational-agent-tp-3654-in-patients-with-myelofibrosis-at-american-society-of-hematology-2022-annual/
35. Sumitomo Pharma Oncology, Inc. Presents Updated Preliminary Data from Phase 1/2 Clinical Study, accessed September 13, 2025, https://www.sumitomo-pharma.com/news/assets/pdf/ene20230612.pdf
36. Paper: Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, Showed Durable Clinical Response and Sustained Hematological Improvement in Relapsed/Refractory Myelofibrosis Patients, accessed September 13, 2025, https://ash.confex.com/ash/2024/webprogram/Paper200312.html
37. EMA Grants Orphan Drug Designation to Nuvisertib for Myelofibrosis - OncLive, accessed September 13, 2025, https://www.onclive.com/view/ema-grants-orphan-drug-designation-to-nuvisertib-for-myelofibrosis
38. Assessment of Relative Bioavailability and Effect of Food on ..., accessed September 13, 2025, https://ctv.veeva.com/study/assessment-of-relative-bioavailability-and-effect-of-food-on-capsule-and-tablet-formulations-of-tp3
39. Sumitomo Pharma America Presents New Data on Nuvisertib and Enzomenib at the 2024 American Society of Hematology Annual Meeting, accessed September 13, 2025, https://news.us.sumitomo-pharma.com/2024-12-09-Sumitomo-Pharma-America-Presents-New-Data-on-Nuvisertib-and-Enzomenib-at-the-2024-American-Society-of-Hematology-Annual-Meeting
40. Sumitomo Pharma America Announces that the European Medicines Agency Has Granted Orphan Drug Designation to Nuvisertib (TP-3654) for the Treatment of Myelofibrosis - Jul 30, 2025, accessed September 13, 2025, https://news.us.sumitomo-pharma.com/2025-07-30-Sumitomo-Pharma-America-Announces-that-the-European-Medicines-Agency-Has-Granted-Orphan-Drug-Designation-to-Nuvisertib-TP-3654-for-the-Treatment-of-Myelofibrosis
41. Development Pipeline - Sumitomo Pharma, accessed September 13, 2025, https://www.sumitomo-pharma.com/rd/pipeline_new-medicine/pipeline.html